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Abstract
Background: Haematopoietic stem cell transplantation (HSCT) has been tried in the last 15 years as a therapeutic 
option in patients with poor-prognosis autoimmune disease who do not respond to conventional treatments. 
Worldwide, more than 600 patients with multiple sclerosis (MS) have been treated with HSCT, most of them having 
been recruited in small, single-centre, phase 1–2 uncontrolled trials. Clinical and magnetic resonance imaging outcomes 
from case series reports or Registry-based analyses suggest that a major response is achieved in most patients; quality 
and duration of response are better in patients transplanted during the relapsing–remitting phase than in those in the 
secondary progressive stage. 
Objectives:  An interdisciplinary group of neurologists and haematologists has been formed, following two international 
meetings supported by the European and American Blood and Marrow Transplantation Societies, for the purpose of 
discussing a controlled clinical trial, to be designed within the new scenarios of evolving MS treatments. 
Conclusions: Objectives of the trial, patient selection, transplant technology and outcome assessment were 
extensively discussed. The outcome of this process is summarized in the present paper, with the goal of establishing 
the background and advancing the development of a prospective, randomized, controlled multicentre trial to assess 
the clinical efficacy of HSCT for the treatment of highly active MS.
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Introduction
Current treatments of multiple sclerosis (MS) include high-
dose corticosteroids for the treatment of exacerbations and 
long-term immuno-modulation/-suppression to reduce the 
number and severity of relapses, and slow down the progres-
sion of disability.1 The intensity of the immunosuppression 
is to some extent proportional to the risk of side effects and 
to the clinical response, expressed in terms of capacity to 
reduce the frequency of relapses (Figure 1).2 However, no 
disease-modifying agent (DMA) has been conclusively 
shown to significantly alter long-term outcomes; moreover, 
a subset of patients presents with aggressive disease which 
responds poorly to conventional treatments. Treatment alter-
natives are especially needed for this group of patients, i.e. 
those failing multiple treatments and rapidly accumulating 
clinical disability.
Haematopoietic stem cell transplantation (HSCT) is a 
well-established procedure for the treatment of poor-prog-
nosis haematological malignancies.3 In the last 15 years 
HSCT has also been explored to treat patients with severe 
autoimmune diseases (AD) who were deteriorating despite 
receiving standard treatments.4 The rationale is derived both 
from experimental models5 and from the observations of 
positive effects on a coincidental AD of transplants given 
for a conventional haematological indication.6
Autologous HSCT for MS has been repeatedly and 
recently reviewed.7 Most patients were treated in small phase 
1–2 trials, either single-8–15 or multi-centric;16,17 currently no 
data are available from prospective comparative trials. Two 
single-centre, retrospective analyses of long-term outcome 
were recently published and both showed a sustained pro-
gression-free survival (PFS) beyond 5 years after HSCT.15,18 
The neurological outcome was considerably more favourable 
in patients transplanted in the relapsing–remitting (RR) 
phase18 and/or showing an inflammatory pattern at magnetic 
resonance imaging (MRI) during pre-transplant screening.15 
Indeed, case series and reports of excellent outcome in par-
ticularly aggressive forms of MS19,20 support the notion of 
efficacy of HSCT in MS patients with prominent inflamma-
tory activity. The risk of treatment-related mortality (TRM) 
in HSCT, conventionally perceived to be unacceptably high, 
has decreased since 2001 to 1.3%, according to an analysis 
of the European Blood and Marrow Transplantation Group 
(EBMT, www.ebmt.org) Registry,7 likely due the avoidance 
of aggressive regimens which resulted in frequent toxicity. 
In particular, the use of busulfan was found to be significantly 
associated with higher TRM in multivariate analysis,21 and 
high doses of rabbit anti-T-lymphocyte globulin (ATG), asso-
ciated with ex-vivo T-cell depletion and an intense condition-
ing regimen (CR), resulted in unexpected occurrence of 
EBV-associated lymphomas.22 In 2004, the EBMT launched 
a prospective, randomized phase 2 trial (ASTIMS, www.
astims.org) comparing autologous HSCT with mitoxantrone, 
with new MRI lesions as the primary endpoint (number of 
new T2 lesions at 1 and 2 years after the randomization). In 
total, 21 patients were randomized to the two trial arms and 
the follow-up analysis is currently ongoing. Two phase 2, 
single-arm trials were carried out in the USA (www.halt-ms.
org; or www.clinicaltrials.gov, id. NCT00288626) and 
Canada (www.clinicaltrials.gov, id. NCT01099930), respec-
tively; both trials closed accrual in 2010. The Canadian trial 
has reported results in preliminary form showing complete 
suppression of relapses and of new MRI lesions in 23 evalu-
able patients over a median follow-up of 5 years.12 The US 
HALT-MS trial preliminary results in 25 patients with highly 
active, treatment-refractory RRMS have reported a 77% 
event-free survival at 2 years post-HSCT utilizing a stringent 
composite endpoint that included relapses, new MRI lesions 
and progression of neurological disability.23
The cumulative experience described above is highly sug-
gestive of a strong treatment effect of HSCT on inflamma-
tory manifestations of MS, but the efficacy and safety of 
HSCT compared with currently available therapies has 
not yet been established. In November 2008 a meeting of 
experts in MS and bone marrow transplantation was held in 
Minneapolis under the auspices of Center for International 
Blood & Marrow Transplant Research (CIBMTR), the 
National Institute of Allergy and Infectious Diseases (NIAID), 
and the EBMT in order to establish shared criteria for the 
assessment of efficacy of HSCT in MS and evaluate the 
feasibility of a new prospective, multicentre trial.24 One year 
later EBMT and NIAID supported an international meeting 
Figure 1.  Estimated efficacy versus risks of approved and 
experimental therapies for MS. The plot indicates estimated, 
approximate risks vs. efficacy measures for some approved and 
experimental MS treatments. Estimated risks of life threatening 
unwanted effects are obtained from data available in the current 
literature.39–50 The percent relapse suppression observed in 
treated patients is presented as a surrogate of efficacy. The list of 
treatments is not meant to be exhaustive but to only include the 
agents that have immediate relevance for the HSCT trial design. 
Abbreviations: GA, glatiramer acetate; IFN-β, interferon beta; 
FTY, fingolimod; Mitox., mitoxantrone; CY, cyclophosphamide, 
Nataliz., natalizumab; Alemt., alemtuzumab, Hi-CY, high-dose 
cyclophosphamide, HSCT, autologous hematopoietic stem cell 
transplantation.
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in Florence, aimed to update knowledge and strategies of 
HSCT for AD. Panels of specialists were appointed for each 
major AD (www.adflorence.org) and the MS panel included 
neurologists, haematologists and statisticians from both 
Europe and North America.25 There was uniform agreement 
about the need for a prospective, controlled trial aimed at 
investigating the role of HSCT in the treatment of aggressive 
MS. This report describes the progress to date of this inter-
disciplinary group of specialists in the design of such a trial.
Choice of trial
Two approaches to a prospective trial were considered 
(Figure 2): a cohort trial, where patients fulfilling homogene-
ous criteria of disability and unsatisfactory response to 
approved treatments are registered, treated according to the 
policy of each participating centre (including the transplanta-
tion option) and prospectively followed-up. This approach 
would likely find higher acceptance and easier implementa-
tion; however, it would be expected to add little knowledge 
to the existing data. Therefore, all panellists agreed that a 
large, international, phase 3, randomized trial with a clinical 
endpoint is currently needed. This should be a phase 3 study 
where patients are randomized between autologous HSCT 
and the appropriate non-HSCT comparator.
Non-HSCT comparator
There was considerable discussion regarding the most appro-
priate comparator. Although some discussants favoured a 
single agent (e.g. natalizumab), there were prevailing concerns 
that some agent/s might not be available in all participating 
countries. Approval of an additional 3–4 new therapies for 
RRMS is foreseen in the next 2 years,1 with differences in 
their introduction expected in different countries due to regu-
latory issues. Furthermore, there is no standard of therapy for 
patients failing approved treatments for MS who are eligible 
for HSCT, therefore they are treated differently according to 
centre policy and local regulations on drugs and reimburse-
ment policies. As a result of these considerations, a consensus 
view emerged that the trial should be designed with randomi-
zation between autologous HSCT and Best Available and 
Approved Treatment (BAAT). The BAAT is defined as, and 
will consist of, the treatment available as licensed therapy to 
the individual patient in his/her country of residence and 
approved under the applicable healthcare scheme.
Trial goals
 • To establish the safety and efficacy of autologous 
HSCT in comparison with approved therapies in a 
specific subset of highly active RRMS;
 • To address questions related to the immunopathogen-
esis of MS by accompanying mechanistic studies;
 • To create a comprehensive repository of biosamples 
for planned and future mechanistic studies.
Inclusion criteria
The definition of inclusion criteria was felt to be a key point. 
The aim of the panellists was to capture a subset of patients 
with relatively early MS who are at high risk of suffering 
Figure 2.  Prospective clinical trials for HSCT in MS. Choice of trial design. BAAT, best available and approved treatment; DMA, 
disease-modifying agent; HSCT, haematopoietic stem cell transplantation.
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early disease progression based on their high inflammatory 
activity. Prognostic predictions are difficult in MS, and three 
domains were considered important to formulate criteria that 
select subjects at greater risk of poor prognosis and potential 
eligibility for the trial: (1) clinically significant relapses; 
(2) MRI activity; and (3) treatment failure. The following 
specific criteria were selected:
 • Patients aged 18–45 years with Expanded Disability 
Status Scale (EDSS) score between 2.5 and 5.5, who 
are within 5 years from initiation of the first therapy 
with DMAs and who fulfil the criteria for highly active 
RRMS within the past 2 years.
○ The definition of ‘highly active’ RRMS includes:
■ ≥1 severe relapses (ΔEDSS ≥1 and Fatigue 
Severity Scale (FSS) of ≥2 in motor, cerebellar 
or brain stem deficit (or documented changes in 
neurological examination consistent with these 
magnitudes) and/or incomplete recovery from 
clinically significant relapses;
and
■ ≥1 gadolinium-positive (Gd+) lesion of diameter 
≥ 3 mm or accumulation of ≥ 0.3 T2 lesions/
month in two consecutive MRI 6–12 months apart.
○ Patients are eligible after failure of conventional 
treatment.
The upper limit of 45 years was chosen for the follow-
ing reasons: (1) the low probability of older patients to 
fulfil the inclusion criteria; (2) their faster shift to the 
secondary progressive phase of disease;26 and (3) one 
report of a worse outcome after HSCT in patients aged 
over 40 years.21
○ Patients must have failed at least one and up to three 
subsequent lines of BAAT. Treatment failure is 
defined as follows:
■ Evidence of relapses, increased EDSS (by 0.5 
for any EDSS ≥5.5 or 1.0 for any EDSS <5.5, 
confirmed after 3 months,27 continuing Gd+ or 
new T2 lesions ≥6 months from starting therapy 
(same as ‘highly active’).
○ Patients will be given the option to be randomized 
after failing only first-line therapy, which may have 
been either an immunomodulating or immunosup-
pressive therapy, (e.g. natalizumab, fingolimod, 
IFN-β, glatimer-acetate).
This last item was extensively discussed since some neu-
rologists consider failure of only first-line therapy as ‘too early’ 
to randomize patients to HSCT. Others consider the above 
criteria for ‘highly active’ MS as an indicator of poor prognosis, 
therefore the randomization at this stage being appropriate. 
Taking all these considerations into account, it was decided 
to allow, but not to require, the inclusion of patients after a 
first-line treatment failure only. Patients will be stratified 
according to the treatments administered before the randomi-
zation, should numbers permit (see Figure 3).
Figure 3.  Prospective, controlled trial for HSCT in a multiple sclerosis. Trial design.
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The informed consent process should include a detailed 
discussion of the treatment risks and non-trial treatment 
alternatives. Patients must be adequately screened to exclude 
coincidental organ failure, to minimize the transplant-asso-
ciated toxicity.
Most of the MS panellists estimated that 8–10 patients 
fulfilling the inclusion criteria present each year at their 
respective institutions (~5% of patients in dedicated MS 
centres with a large base of annual referrals).
Outcomes of the study
A major response should be expected by an aggressive treat-
ment involving significant risk such as HSCT. Such response 
could be defined as PFS lasting 5 years free from further 
immunosuppressive treatment. A long-term follow-up, such 
as the proportion of patients still progression-free at a given 
interval (e.g. 3 or 5 years), would greatly increase the dis-
crimination power between the two treatment arms; however, 
there was consensus that a follow-up duration longer than 
2 years before assessing the primary outcome would not be 
feasible for the core trial. In the ASTIMS trial, randomization 
prior to HSCT hampered recruitment, due to the rapidly evolv-
ing clinical course of patients; this concern should be carefully 
considered in the trial design. For this reason, we favoured a 
‘time to event’ endpoint, allowing patients initially rand-
omized to BAAT who continue to deteriorate to cross-over 
to HSCT once they have reached the ‘time to’ endpoint.
 • The primary outcome is the time to treatment failure, 
compared between treatment arms.
○ Definition of treatment failure is the occurrence of 
a severe relapse (see above) or sustained EDSS 
worsening (i.e. increase by 0.5 for any EDSS ≥5.5 
or 1.0 for any EDSS <5.5, confirmed after 3–6 
months), or a new (Gd+) lesion ≥3 mm or accumula-
tion of >0.3 mm T2 lesions/month in two consecu-
tive MRI 6–12 months apart.
Patients reaching the primary endpoint will be given the 
chance to receive the treatment of the other arm (i.e. HSCT 
in case of failure of the control treatment; and vice versa).
This primary endpoint optimizes the trial design, in that 
it requires a shorter follow-up as compared with a 2-year 
trial based on a relapse rate endpoint, and preserves a similar 
statistical power, especially in case of early post-treatment 
treatment failure events. The option to cross-over for patients 
reaching the endpoint will facilitate the availability of patients 
for a randomized trial.
Secondary objectives will include:
○ Comparison of overall survival;
○ Treatment-related mortality;
○ MRI outcomes including lesion and atrophy metrics, 
to be defined;
○ Rates of disease progression;
○ Rate of adverse events, infectious complication;
○ Quality of life;
○ Improvement of disability;
○ Response to post-failure treatment between treatment 
arms; and
○ Need for any MS-related treatment.
Sample size
We calculated that 114 patients (57 in each group) are 
required to provide a power of 90% (at a confidence level 
of 5%) to detect a clinically meaningful relative reduction 
in the actuarial cumulative probability to have a failure over 
1 year of 50% (corresponding to a hazard ratio (HR)=0.44) 
in the HSCT group as compared with the BAAT group.
Sample size was calculated by using a log-rank test on 
the assumption that 40% of failures would occur in the BAAT 
group at 1 year, with an exponential distribution for time 
to failure, with an accrual time of 1 year and a follow-up of 
2 years.
Transplant methodology
The intensity of the immunosuppression delivered by the 
transplant treatment is dependent upon several factors:
1. The use of chemotherapy, such as cyclophosphamide 
(Cy) in the stem cells mobilization regimen;
2. Ex-vivo T-cells depletion (purging);
3. An intense CR;
4. The inclusion of ATG or monoclonal antibodies (i.e. 
alemtuzumab) in the CR to maximize the immuno-
suppression (Figure 4).
The overall intensity of the treatment can be modulated 
by changing the combination of such variables used (from 
none to all of them). The initial experiences of autologous 
HSCT for MS were dominated by high-intensity regimens 
as a high rate of relapse was expected, following some initial 
reports in ADs.28 With time, toxicity of such regimens became 
a clinical issue,21,22,29 and at the same time evidence emerged 
that less aggressive treatments have a favourable risk/benefit 
profile, as recently reviewed.30 Indeed, the importance of the 
disease phase (RRMS vs. secondary progressive MS) over 
the intensity of CR in determining the outcome was increas-
ingly perceived by the teams involved in transplant pro-
grammes,15,18 and this is reflected by the gradual increase in 
RRMS cases treated being reported to the EBMT Registry 
over the years (Figure 5).
The most widely used CR in Europe for MS is the inter-
mediate-intensity BEAM/ATG regimen (Carmustine, 
Etoposide, ARA-C and Melphalan in combination with poly-
clonal rabbit ATG).21 This regimen is still widely used due 
to the good safety/efficacy profile in lymphoproliferative 
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diseases. BEAM has more recently been included in MS 
trials in Asia31 and in the USA (www.halt-ms.org). A lower-
intensity (non-myeloablative) regimen, based on Cy and 
ATG or alemtuzumab, was also reported from Burt and col-
leagues at Northwestern University32 in a group of patients 
with early RRMS. The analysis of outcomes showed a low 
Figure 4.  Transplant methodology. The boxes represent variables related to the intensity of the treatment. (from Saccardi R and 
Gualandi F. Autoimmunity, 2008; 41(8): 570-576.)
Figure 5.  Proportion of multiple sclerosis forms at transplant baseline across the years. EBMT Registry data.
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toxicity, but a trend to a higher frequency of relapses or 
recurrence of MRI activity (23%) than in higher-intensity 
CRs, although patients were reported to respond well to fur-
ther immunotherapies. A prospective comparative trial would 
be needed to draw conclusions about its safety and efficacy 
profile.
○ Mobilization of stem cells
 • Patients will be mobilized by the administration of 
cyclophosphamide, 4 g/m2 followed by G-CSF, 10 
mcg/kg. Peripheral blood stem cells (PBSC) will 
be collected by continuous flow leukapheresis, tar-
geted to cryopreserve ≥3×106 CD34+ cells/kg.
The combination of Cy and G-CSF is preferred because
1. Most patients improve after mobilization that includes 
a standard (2–4 g/m2) Cy regimen;17
2. Cy reduces the potential risk of MS exacerbation in 
response to G-CSF;33
3. Inclusion of Cy in the mobilization regimen decreases 
the number of T cells in the apheresis collection, pos-
sibly obviating the need for ex-vivo T-cell depletion;
4. Although comparative data are not available, no post-
transplant carryover of T-cell clones was shown to 
have originated from a Cy-mobilized CD34-selected 
hematopoietic graft.34
○ Graft manipulation
■ PBSC will be cryopreserved unmanipulated.
Ex-vivo T-cell depletion techniques such as CD34+ selec-
tion were proven to be ineffective in a prospective compara-
tive trial for rheumatoid arthritis35 and in a retrospective 
analysis of the MS EBMT database.21 Moreover, the feasi-
bility of the study would be improved and transplant costs 
would be reduced by using unmanipulated grafts.
○ CR
■ ‘BEAM’ regimen (BCNU 300 mg/m2 on day -6, 
cytosine arabinoside, 200 mg/m2 and etoposide 
200 mg/m2 day -5 to day -2, melphalan 140 mg/
m2 day -1) + peri-transplant ATG is preferred by 
most of the transplanters as an intermediate-
intensity regimen.
BEAM+ATG is the most commonly used regimen in 
Europe, and it showed a satisfactory toxicity profile both in 
the EBMT Registry analysis21 and in the North American 
Halt-MS trial.36 Low-intensity regimens (i.e. Cy+alemtuzumab 
or ATG) do not seem likely to achieve the goal of 5 years of 
disease and treatment-free survival, when considering the 
only prospective trial reported so far.32 A Brazilian prospec-
tive study compared BEAM/ATG vs. Cy/ATG, reporting a 
similar outcome but a lower toxicity in the latter. However, 
the patients included in both groups all had advanced disease, 
which limited the usefulness of the comparison; also, a high 
dose of horse ATG was administered in the BEAM group, 
and may have caused the high observed toxicity (TRM 7.5%) 
which exceeds any other report.37 Finally, high-intensity 
regimens (i.e. busulphan + Cy) can also be considered; it is 
thought that toxicity might be higher, but with the advent of 
intravenous formulations of busulphan and monitoring of 
blood levels, this might be minimized, as reported in the 
Canadian trial.12 All the participants agree that data from the 
Canadian trial are highly promising. However, the choice of 
the CR for a large, prospective, multicentre trial needs to be 
based on published data either from prospective studies and/
or from Registry analysis, and therefore BEAM was consid-
ered the best choice at the current time. New published data 
on the CR might change the current preference.
Immunological studies and 
repository of biosamples
The demonstration by Muraro et al.38 that autologous HSCT 
indeed leads to extensive renewal of the T-cell repertoire 
provided crucial evidence to document that autologous HSCT 
goes beyond a profound and long-lasting immunosuppres-
sion, which can be achieved by conventional treatments. 
However, many questions remain regarding the therapeutic 
mechanisms of autologous HSCT, and these should be exam-
ined during the prospective phase 3 trial. Therefore, a com-
prehensive repository of biomaterials should be created in 
order to allow interested investigators to address important 
questions in parallel with the trial and later. An assessment 
of immune reconstitution will be integrated in the trial and 
will be carried out on freshly collected blood specimens. A 
policy will regulate the utilization of the stored biological 
samples for qualified research projects, and its implementa-
tion will be overseen by a specific study committee.
Logistics and funding
The target population of the trial constitutes a relatively small 
subset of all patients with RRMS, and in order to meet patient 
accrual within a period of 2 years a large number of countries 
and participating centres need to be involved. Currently a 
clear sign of interest has been received from groups in Canada, 
France, Germany, Italy, Switzerland, the USA, and the UK. 
Other centres in Brazil, Spain, and the Czech Republic might 
follow. Each centre will need an established team of MS 
neurologists and bone marrow transplanters, as well as access 
to facilities including MRI and a laboratory infrastructure for 
the collection, characterization and storage of the biological 
samples for research. Criteria will be established to select 
centres with the required capacity and experience. Nursing 
care will require interaction between neurological and hae-
matological nursing staff. A comprehensive plan for data 
collection, management, quality control and analysis for this 
complex international study will need to be developed.
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Conducting a phase 3 controlled multi-centre trial com-
paring a treatment such as autologous HSCT with other treat-
ments will not only be a major organizational effort, but will 
also be expensive. We do not expect a high level of interest 
in autologous HSCT for treatment of MS from pharmaceuti-
cal companies, which may even consider the treatment as 
market competition. Therefore, funding will have to be 
sought from public funding bodies and charitable founda-
tions. A strategy for funding should consider and coordinate 
public resources at the international (NIH, EU FP-7 or later 
framework programmes), national (MS societies, national 
research foundations, governmental funding calls, others), 
and local (at the respective centres, their universities, cities 
or states) level.
Conclusions
We believe that the proposed outline protocol represents a 
solid foundation for the development of a randomized con-
trolled phase 3 trial of HSCT for MS. Interested neurologists, 
bone marrow transplanters and MS patient associations are 
invited to engage in the final stages of protocol development 
and in the trial planning.
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